Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

58
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
58
T Cell Types and Functions01:24

T Cell Types and Functions

3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
Autoimmune Disorders01:29

Autoimmune Disorders

2.4K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sub-Tenon Block with Bolus-Free Dexmedetomidine Sedation for Penetrating Keratoplasty: A Retrospective Clinical Case Series of 50 High-Risk Patients.

Life (Basel, Switzerland)·2026
Same author

Gephyrin Neurological Autoimmunity.

Annals of neurology·2026
Same author

Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.

Lancet (London, England)·2026
Same author

Lyophilized Amniotic Membrane Eye Drops Stabilize the Tear Film in Dry Eye Disease: A Prospective Cohort Study.

Journal of clinical medicine·2026
Same author

The effect of optical flow perturbations on walking foot placement control in people with multiple sclerosis.

Journal of biomechanics·2026
Same author

Neutrophil Extracellular Traps in Exocrine Pancreatic Disease: A Comprehensive Review of Pathogenesis, Severity Stratification, and Therapeutic Targeting.

Cells·2026

Related Experiment Video

Updated: May 5, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.9K

Interferon-beta and disability progression in relapsing-remitting multiple sclerosis.

Jelena Drulovic1, Jelena Kostic, Sarlota Mesaros

  • 1Clinic of Neurology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Dr Subotica 6, 11129 Belgrade, Serbia.

Clinical Neurology and Neurosurgery
|December 11, 2013
PubMed
Summary

Interferon-beta treatment significantly reduced the risk of secondary progression and sustained disability in relapsing-remitting multiple sclerosis (RRMS) patients. This observational study suggests a beneficial effect of interferon-beta on RRMS disease progression.

Keywords:
Disease progressionInterferon-betaMultiple sclerosisObservational studyPrognosis

More Related Videos

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

10.6K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K

Related Experiment Videos

Last Updated: May 5, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.9K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

10.6K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K

Area of Science:

  • Neuroimmunology
  • Clinical Neurology
  • Therapeutic Research

Background:

  • Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Relapsing-remitting MS (RRMS) is the most common form, characterized by distinct attacks and remissions.
  • Assessing the long-term impact of disease-modifying therapies is crucial for managing MS progression.

Purpose of the Study:

  • To evaluate the effect of interferon-beta (IFN-beta) treatment on the progression of disability in RRMS patients.
  • To compare disease progression between RRMS patients treated with IFN-beta and those who were untreated.
  • To analyze the impact of IFN-beta on secondary progression and sustained Expanded Disability Status Scale (EDSS) scores.

Main Methods:

  • Prospective cohort study of 419 RRMS patients (236 treated, 183 untreated) followed for up to 7 years.
  • Cox proportional hazards regression models were used to compare outcomes between treated and untreated groups.
  • Adjustments were made for the number of relapses in the year preceding the study to account for baseline disease activity.

Main Results:

  • IFN-beta treated patients showed a significant reduction in the risk of secondary progression (HR=0.34, p<0.001) compared to untreated patients.
  • A significant benefit was observed for IFN-beta treated patients regarding sustained EDSS scores of 4 (HR=0.45, p=0.001) and 6 (HR=0.34, p=0.007).
  • These findings indicate a protective effect of IFN-beta against long-term disability accumulation in RRMS.

Conclusions:

  • This observational study provides further evidence supporting the beneficial role of IFN-beta in mitigating disease progression in RRMS.
  • IFN-beta treatment appears to slow down the accumulation of disability in patients with relapsing-remitting multiple sclerosis.
  • The results underscore the importance of early therapeutic intervention in managing MS.